Categories Analysis, Earnings, LATEST, Other Industries

Earnings Preview: Raw material costs likely to weigh on 3M Q3 results

3M Company (MMM) is scheduled to report earnings results for the third quarter of 2018 on Tuesday, October 23. Analysts expect the company to report earnings of $2.70 per share on revenues of $8.4 billion. This would reflect a growth of 3% in revenue and 15.9% in earnings on a year-over-year basis.

The company has never missed market expectations in the past four quarters. Results have either matched or topped estimates and can be expected to do the same for the to-be reported quarter.

For the third quarter, 3M is expected to see year-over-year revenue growth across all its segments. Other factors that could benefit the company include strong products, strategic portfolio reviews and innovation as well as stable end-market demand.

The factors that could hurt 3M include tough competition, negative impacts from foreign currency and higher expenses. The company can expect continued pressure from increases in raw material costs for the third quarter and the foreseeable future.

In the second quarter, 3M delivered better-than-expected results, with a 7% increase in revenue and a 19% improvement in EPS. The revenue growth was driven by a 15.8% sales increase in the safety and graphics business. The company also recorded a benefit of $0.48 per share from the divestiture of its communication markets business in the quarter.

3M reports 7.4% rise in revenue

Last quarter, 3M updated its full-year 2018 earnings guidance to reflect the impact from the divestiture. GAAP EPS is expected to be $9.08 to $9.38 while adjusted EPS is expected to be $10.20 to $10.45.

3M’s shares have dropped more than 14% year to date. Looking at the past one month, the stock is down 5%.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top